Pharminox Ltd

http://www.pharminox.com

Pharminox was formed in 2002 as a spin-out from Oxford University.

We are focused on the discovery and development of novel small molecule drugs for the treatment of cancer. In early 2004, Malcolm Stevens, Director of the Cancer Research UK Experimental Cancer Chemotherapy Group, joined Pharminox as Chief Scientific Officer. Our discovery activities are now based at our new laboratories at the BioCity facility in the centre of Nottingham.

We have world class expertise in medicinal chemistry and our approach to drug discovery is very much chemistry-driven.

We are progressing a number of innovative discovery programmes which include completely new classes of anti-cancer agent with novel mechanisms of action, offering the prospect of first in class compounds. Over time we intend to build our pipeline through continuing internal drug discovery combined with selective acquisition of appropriate external research and development opportunities.

Our in-licensing activities are intended to identify late stage discovery and early stage clinical development programmes which can complement our own internal activities, thus creating an innovative drug development portfolio ranging from early stage discovery through to clinical proof of concept.

We have an experienced management team, led by Peter Worrall, with the expertise and collaborative network to undertake, on a virtual basis, the complicated process of drug development.

With our people and our portfolio we believe that we have in place the building blocks to become a major force in oncology research and development within the UK over the next few years.